RESEARCH MONOGRAPH · KDC-MN-322

Cannabinol (CBN)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

49/100

Mostly a marketing story about sleep with very thin actual evidence

Honestly, CBN is the cannabinoid we have the hardest time getting excited about. The consumer narrative is that it's the 'sleep cannabinoid' from aged cannabis, and the pharmacology backing that claim is genuinely thin.

Heres what's actually known. CBN is a partial CB1 agonist with maybe a quarter of THC's affinity, weaker CB2 activity, and not much else in the binding profile that distinguishes it. It forms as THC degrades by oxidation, which is why old cannabis tests higher in CBN, and the legend that aged cannabis is sedating got rolled into 'CBN causes sedation' decades ago without ever being properly tested. The actual human trial data on CBN as a sleep aid is essentially one published Karniol study from 1975 with 5 subjects, and a handful of small more recent studies that mostly show no significant effect over placebo or CBD. Thats it.

What we know more clearly: it's a weak partial CB1 agonist that does produce some THC-like effects at high doses, mostly attenuated. There's some interesting work on CBN in MRSA models (Appendino) and some antiinflammatory signal, but those arent the sleep claim.

The current crop of CBN sleep products are selling 3-10 mg doses based on essentially no controlled human evidence for that indication. The honest answer is that CBN might do something for sleep in some people, but the evidence base would not survive any rigorous review, and most of what people are paying for is probably placebo plus whatever residual THC and CBD are in the formulation.

Sourcing-wise it's straightforward to obtain high-purity material now (synthetic or isolated), HPLC characterization is fine, prices have come down as supply caught up with demand. Stability is okay, oxidative degradation is the main concern.

What we like: it does have real CB1 partial agonist activity and as a research tool for low-efficacy CB1 work it has a niche.

What we dont like: the entire sleep-aid market built around it, which is well ahead of any reasonable read of the actual evidence.

If the marketing went away tomorrow we wouldnt particularly miss this molecule outside specific cannabinoid pharmacology research. Honest take: probably underdelivers.

Evidence: 25
Mechanism: 55
Reliability: 35
Safety: 80
Sourcing: 78
Value: 40
Signal: 40
Staying power: 40

Plain-language summary Intrigue 38 / 100

Cannabinol is what THC slowly turns into when cannabis ages and oxidizes, which is why old or improperly stored flower accumulates higher CBN levels. It retains weak partial agonism at the CB1 receptor (about 10 percent of THC potency) and so is mildly intoxicating at high doses. The supplement industry markets CBN heavily as a sleep aid, but the human clinical evidence behind that claim is thin, mostly extrapolated from one small 1970s study where CBN was given alongside THC. Without controlled trials separating the two, the sleep-specific case for CBN remains poorly supported. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Phytocannabinoid (THC degradation product)

A phytocannabinoid produced by THC oxidation in aged cannabis; weakly intoxicating; widely marketed as a sleep aid despite limited clinical evidence.

Abstract

Cannabinol (CBN; CAS 521-35-7; molecular formula C21H26O2; molecular weight 310.43) is a phytocannabinoid formed primarily by oxidative degradation of THC; aged cannabis develops higher CBN concentrations. The compound retains weak CB1 partial agonist activity (approximately 10 percent of THC potency at CB1), producing mild psychoactive effects at high doses. CB2 affinity is comparable to or higher than CB1. Pharmacologically distinguished from THC by the aromatized A-ring, which reduces CB1 binding but preserves other interactions. Marketing claims position CBN as a sleep aid; clinical evidence for this is limited (one 1976 trial and small subsequent studies), and the sedation may largely reflect residual THC contamination in early CBN samples. Plasma kinetics parallel other cannabinoids. Used as a CB receptor partial agonist research compound; the sleep marketing claims await rigorous clinical validation.

Mechanism of action

Oxidation product of THC; weak CB1 partial agonist (~10 percent of THC potency); CB2 activity comparable. Sedative claims poorly substantiated.

Reported research dose ranges

Supplement use 2.5 to 25 mg in the published literature before sleep; clinical evidence sparse.

References

Karniol IG, et al. Effects of delta-9-tetrahydrocannabinol and cannabinol in man. Pharmacology 1975.
Bonn-Miller MO, et al. Cannabinol for sleep: an evidence review. Sleep Med Rev 2022.
Russo EB. Cannabis pharmacology: the usual suspects and a few promising leads. Adv Pharmacol 2017.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-322

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Cannabinol (CBN)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs